Fusion protein comprising FK506 binding protein and DNA...

Details Fusion protein comprising FK506 binding protein and DNA... Fusion protein comprising FK506 binding protein and DNA...

2011-03-08

2011-03-08

Bunner, Bridget E (Department: 1647)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023400, C530S350000

Reexamination Certificate

active

07902346

ABSTRACT:
Disclosed is a fusion protein containing a FK506 binding protein and a cell-transducing domain. Also, disclosed is a method of making the fusion protein and use of the fusion protein in a pharmaceutical or cosmetic composition. The cell-transducing domain is, for example, a PEP-1.

REFERENCES:
patent: 6387700 (2002-05-01), Rice et al.
patent: 2004/0075236 (2004-08-01), None
patent: 2005/0005659 (2005-01-01), None
patent: 2006/0017348 (2006-02-01), None
patent: WO 97/38011 (1997-10-01), None
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotech 18(1): 34-39, 2000.
Bork, A. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Res 10: 398-400, 2000.
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics 14(6): 248-250, 1998.
Smith et al. The challenges of genome sequence annotation or “The devil is in the details”. Nature Biotech 15: 1222-1223, 1997.
Brenner, S.E. Errors in genome function. Trends in Genetics 15(4): 132-133, 1999.
Bork et al. Go hunting in sequence databases but watch out for the traps. Trends in Genetics. 12(10): 425-427, 1996.
Wells. J.A. Additivity of mutational effects in proteins. Biochemistry 29 (37): 8509-8517, 1990.
Ngo et al. Computational complexity, protein structure prediction, and the Levinthal paradox. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
Wang et al. The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors. Frontiers in Biosci 9: 619-631, 2004.
Woo et al. Topical tacrolimus: a review of its uses in dermatology. Dermatitis 16(1): 6-21, 2005.
Magzoub et al. Cell-penetrating peptides: small from inception to application. Quart Rev Biophys 37(2): 147-195, 2004.
Chow et al. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opin Drug Saf 6(5): 479-485, 2007.
Kang et al. FKBP family proteins: immunophilins with versatile biological functions. Neurosignals 16: 318-325, 2008.
Barik et al. Immunophilins: for the love of proteins. Cell Mol Life Sci 63: 2889-2900, 2006.
Jarver et al. The use of cell-penetrating peptides as a tool for gene regulation. Drug Disc Today 9(9): 395-402, 2004.
Fong et al. Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family. Proc Natl Acad Sci USA 100(24): 14253-14258 and supplemental pp. 1-3, 2003.
Bang et al., “Activation of Ca2+signaling in neurotrophils by the mast cell-released immunophilin FKBP12”,Proc. Natl. Acad. Sci. USA, 92: 3435-3438. (1995).
Boguniewicz et al., “Atopic dermatitis”,J. Allergy Clin. Immunol. 117(2): S475-S480. (2006).
Bornhövd et al., “Macrolactam immunomodulators for topical treatment of inflammatory skin diseases”,J. Am. Acad. Dermatol. 45(5): 736-743. (2001).
Bradford, M.M., “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding”,Anal. Biochem. 72: 248-254. (1976).
Breuer et al., “Topical immunomodulators in the treatment of atopic dermatitis”,J. Lab. Med. 28(3): 284-287 (2004).
Castro, A.P.B.M. “Calcineurin inhibitors in the treatment of allergic dermatitis”,J. Pediatr. (Rio J) 82(5 Suppl): S166-S172. (2006).
Del Zoppo et al., “Trends and future developments in the pharmacological treatment of acute ischaemic stroke”,Drugs, 54(1): 9-38. (1997).
Fruman et al., “The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells”,J. Immunol. 154: 1846-1851. (1995).
Leung et al., “Atopic dermatitis”,The Lancet, 361: 151-160. (2003).
Leung, D.Y.M., “Atopic dermatitis: New insights and opportunities for therapeutic intervention”,J. Allergy Clin. Immunol. 105: 860-876. (2000).
Matsuda et al., “Regulation of MAPK signaling pathways through immunophilin-ligand complex”,Curr. Top. Med. Chem. 3: 1358-1367. (2003).
Morris et al., “A peptide carrier for the delivery of biologically active proteins into mammalian cells”,Nat. Biotech. 19: 1173-1176. (2001).
Novak et al., “Immune mechanisms leading to atopic dermatitis”,J. Allergy Clin. Immunol. 112(6): S128-S139. (2003).
Panhans-Groβ et al., “Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506)”,J. Allergy Clin. Immunol. 107: 345-352. (2001).
Reitamo, S., “Tacrolimus: A new topical immunomodulatory therapy fro atopic dermatitis”,J. Allergy Clin. Immunol. 107: 445-448. (2001).
Sambrook et al., “Molecular cloning: Preparation of Plasmid DNA . . . ”,Cold spring harbor laboratory press, Cold spring harbor. pp. 1.32-1.42. (1989).
DeCenzo, Maureen et al., “FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes,” Protein Engineering, 1996, vol. 9, No. 2, pp. 173-180.
Fulton, Kate F. et al., “Energetic and structural analysis of the role of tryptophan 59 in FKBP12,” Biochemistry, 2003, vol. 42, No. 8, pp. 2364-2372.
Futer, Olga et al., “FK506 binding protein mutational analysis,” The Journal of Biological Chemistry, Aug. 11, 1995, vol. 270, No. 32, pp. 18935-18940.
Gros, Edwige et al., “A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction,” Biochimica et Biophysica Acta, 2006, vol. 1758, pp. 384-393.
Henriques, Sonia T. et al., “Re-evaluating the role of strongly charged sequences in amphipathic cell-penetrating petides; a fluorescence study using pep-1,” FEBS Letters, 2005, vol. 579, pp. 4498-4502.
Parsons, Janey N. et al., “Regulation of calcineurin phosphatase activity and interaction with the FK-506•FK-506 binding protein complex,” The Journal of Biological Chemistry, Jul. 29, 1994, vol. 269, No. 30, pp. 19610-19616.
Weller, K. et al., “Biophysical and biological studies of end-group-modified derivatives pep-1,” Biochemistry, 2005, vol. 44, No. 48, pp. 15799-15811.

Affiliated with

Also associated with

Rating

Fusion protein comprising FK506 binding protein and DNA... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fusion protein comprising FK506 binding protein and DNA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion protein comprising FK506 binding protein and DNA... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2747721